Compare BioNTech SE - ADR (BNTX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Phillips 66 — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while Phillips 66 trades at $225.41 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 3.8× BioNTech SE - ADR's market cap, and Phillips 66 pays a 2.26% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PSX | |
|---|---|---|
Market Cap | $23.31B | $89.52B |
Sector | Health | Energy |
52-Week High | $119.34 | $224.36 |
52-Week Low | $83.89 | $120.04 |
Enterprise Value | $6.60B | $105.99B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Phillips 66 (PSX) trades at $225.04, up 4.41% today, reflecting strong momentum after Q2 2026 earnings beat. The stock shows bullish technical signals with support near $220 and resistance at $227. Fundamentally, the company reported robust Q2 EPS of $9.41, exceeding estimates, driven by high refining margins and operational efficiency. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream assets.
Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a price target of $221.92. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical factors affecting energy markets. The stock's valuation metrics, like P/E of 12.81, suggest room for upside if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
